
Please try another search
Endo, Inc. operates as a specialty pharmaceutical company that develops, manufactures, markets, and sells various pharmaceutical products and provides life-enhancing therapies in the United States and internationally. It offers specialty medicines, sterile injectables, and generic products. The company offers products for the treatment of conditions in urology, orthopedics, and endocrinology. It also develops additional indications for XIAFLEX in clinical development, including plantar fibromatosis and plantar fasciitis, as well as others in pre-clinical development, including arthrofibrosis of the knee following knee arthroplasty. The company offers ADRENALIN, a non-selective alpha and beta adrenergic agonist indicated for emergency treatment of certain allergic reactions, including anaphylaxis; VASOSTRICT, a product indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines; and APLISOL, a sterile aqueous solution of a purified protein derivative for intradermal administration for aid in the diagnosis of tuberculosis. In addition, it offers SUPPRELIN LA, a soft flexible 12-month hydrogel implant based on hydrogel polymer technology that delivers histrelin acetate, a gonadotropin-releasing hormone agonist, and is indicated for the treatment of CPP in children; AVEED, a long-acting testosterone undecanoate for injection for the treatment of hypogonadism; TESTOPEL, a unique, long-acting implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; and EDEX, a penile injection used to treat erectile dysfunction caused by conditions affecting nerves, blood vessels, emotions and/or a combination of factors. It provides solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, patches, powders, ophthalmics, and sprays. The company was founded in 1997 and is based in Malvern, Pennsylvania with additional offices in Dublin, Ireland; and Woodcliff Lake, New Jersey. It has manufacturing facilities across the United States and India. As of August 1, 2025, Endo, Inc. operates as a subsidiary of Mallinckrodt PLC.
Name | Age | Since | Title |
---|---|---|---|
Paul S. Herendeen | 69 | 2024 | Independent Chairman of the Board |
Matthew Peters | - | 2025 | President, Treasurer & Director |
Mark Tyndall | 48 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review